The ALEX trial showed that alectinib significantly improved progression-free survival compared to crizotinib in untreated ALK-positive NSCLC patients [4]. Similarly, the CROWN trial revealed that lorlatinib was superior to crizotinib in the first-line treatment of advanced ALK-positive NSCLC [5]. Here, ALK is linked to non-small cell lung carcinoma.